Patent ID: 9625473
Date: 2017-04-18
CPC Classifications: A61K,A61P,C07K,G01N

Claim:
1. A method for treating a human subject afflicted with multiple sclerosis or a single clinical attack consistent with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of: a) determining whether the human subject is a glatiramer acetate responder by evaluating IFN-γ concentration in a supernatant of PBMCs derived from the human subject's blood, which human subject can be identified as a glatiramer acetate responder by steps comprising, b) administering the pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier to the human subject only if the human subject is identified as a glatiramer acetate responder, wherein the human subject is a naive patient or wherein the human subject has been previously administered a multiple sclerosis drug other than glatiramer acetate.